Improve Your Commercial Growth Strategy with Custom-Tailored Intelligence

Posts From the monthly archives: "November 2012"

UK lagging behind with bowel cancer drug test A study funded by Merck Serono (distributors of cetuximab outside of North America; CDx biomarkers for cetuximab = EGFR+ and KRAS-) found that only 44% of all bowel cancer patients in the UK received testing for KRAS mutations (test price = £120, refunded by Merck Serono). There…(Read More)